Aarti Drugs Limited
₹435.70-₹13.25 (-3.0%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹3,604 Cr
- P/E
- 18.9x
- EV / EBITDA
- 14.1x
- Revenue
- ₹2,174 Cr
- Net margin
- 6.3%
- ROCE
- 16.3%
Price chart
Technical chartScreen technicals →-13.2% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +1.2%
- 3M
- +5.6%
- 6M
- +16.2%
- 1Y
- -13.2%
- 5Y
- -24.6%
52-week range
Day change -₹13.25 (-3.0%) from ₹449 to ₹436 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in AARTIDRUGS, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Comfortable interest coverage of 8.2x
Concerns0
Rule-based from financial data. Not advice.
About the company
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally.
Read moreShow less
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.
- Sector
- Materials
- Shares outstanding
- 9.1 Cr shares
- ISIN
- INE767A01016
- BSE code
- 524348
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹3,604 Cr
- P/E
- 18.9x
- P/B
- 2.7x
- EV / EBITDA
- 14.1x
- EV / Sales
- 1.7x
- P/S
- 1.6x
- Earnings yield
- 5.3%
- 52-week high
- ₹519.50
- 52-week low
- ₹319.40
Profitability
- Operating margin
- 11.9%
- Net margin
- 6.3%
- EBITDA margin
- 12.0%
- ROE
- 12.1%
- ROCE
- 16.3%
- ROA
- 6.5%
- Dividend payout
- 6.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 2.1%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹2,174 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -4.1%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 6.8%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹273 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -5.2%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 10.6%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 0.9%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹337 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 108.0%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -1.1%
Solvency and efficiency
- Current ratio
- 2.35
- Debt / Equity
- 0.40
- Debt / Assets
- 0.22
- Debt / EBITDA
- 1.74
- Interest coverage
- 8.15
- Financial leverage
- 1.85
- CFO / Net profit
- 2.37
- Cash / Market cap
- 33.2%
- Cash per share
- ₹130.97
- Asset turnover
- 1.04
- Fixed asset turnover
- 3.14
- Capital intensity
- 0.32
- Debtor days
- 104 days
- Inventory turnover
- 3.41
- Cash conversion cycle
- 115 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹7 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹1,909 Cr |
| Sales | Operating profit | ₹265 Cr |
| Operating profit | Interest | ₹32 Cr |
| Operating profit | Depreciation | ₹48 Cr |
| Operating profit | Profit before tax | ₹185 Cr |
| Other income | Profit before tax | ₹14 Cr |
| Profit before tax | Tax and other | ₹42 Cr |
| Profit before tax | Net profit | ₹157 Cr |
Revenue and net profit
Revenue fell 4.1% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹1,915 Cr | ₹258 Cr |
| FY2022 | ₹2,251 Cr | ₹195 Cr |
| FY2023 | ₹2,498 Cr | ₹153 Cr |
| FY2024 | ₹2,267 Cr | ₹142 Cr |
| FY2025 | ₹2,174 Cr | ₹157 Cr |
Cash flows
FY2025: ₹220 Cr from operations, ₹85.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹154 Cr | ₹85 Cr |
| FY2022 | ₹40 Cr | -₹85 Cr |
| FY2023 | ₹162 Cr | ₹31 Cr |
| FY2024 | ₹337 Cr | ₹150 Cr |
| FY2025 | ₹220 Cr | ₹85 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹2,174 Cr-4.1%1Y
- Net profit
- ₹157 Cr+10.6%1Y
- Cash from operations
- ₹220 Cr
- Free cash flow
- ₹85 Cr-43.3%1Y
- Revenue CAGR, 5Y
- 6.8%
- EBITDA CAGR, 5Y
- 1.2%
- Net profit CAGR, 5Y
- 0.9%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹2,174 Cr | ₹265 Cr | — | ₹157 Cr | ₹220 Cr | ₹85 Cr | 12.5% | -4.1% | +10.6% |
Monthly returns
Month-by-month returns of AARTIDRUGS across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹2,273 Cr |
| Equity capital | ₹91 Cr |
| Reserves | ₹1,160 Cr |
| Borrowings | ₹516 Cr |
| Other liabilities | ₹506 Cr |
| Assets | ₹2,273 Cr |
| Fixed assets | ₹761 Cr |
| Capital work in progress | ₹273 Cr |
| Investments | ₹42 Cr |
| Other assets | ₹1,196 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
AARTIDRUGS trades at 18.9x earnings against a peer median of 35.5x (a 47% discount).
Not shown (no positive earnings and no EV / Sales): BN AGROCHEM LIMITED.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Aarti Drugs LimitedAARTIDRUGSthis companyP/E ↓ discount | ₹3,604 Cr | 18.9x | 2.7x | 12.1% | 14.1x |
| HeidelbergCement India LimitedHEIDELBERG | ₹3,825 Cr | 29.7x | 2.9x | — | — |
| Stylam Industries LimitedSTYLAMIND | ₹3,718 Cr | 29.8x | 5.1x | 23.9% | 19.1x |
| Foseco India LtdFOSECOIND | ₹3,548 Cr | 43.0x | 8.1x | — | — |
| Gujarat Alkalis & Chemicals Ltd.GUJALKALI | ₹3,537 Cr | 65.5x | 0.6x | -2.1% | 17.0x |
| Vishnu Chemicals LimitedVISHNU | ₹3,484 Cr | 46.8x | 4.2x | 14.9% | 20.6x |
| Neogen Chemicals LimitedNEOGEN | ₹3,443 Cr | 69.7x | 4.1x | 5.4% | 29.5x |
| ORIENT CEMENT LIMITEDORIENTCEM | ₹3,400 Cr | 11.1x | 1.6x | 10.0% | 7.4x |
| BN AGROCHEM LIMITEDBNAGROCHEM | ₹3,398 Cr | — | 10.6x | -4.2% | -1133.0x |
| Peer median | — | 35.5x | 3.7x | 12.9% | 19.2x |
Year-to-date ROI
AARTIDRUGS since 1 January, against earlier years.
Historical volatility
AARTIDRUGS's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 21.0% |
| FY2022 | 14.0% |
| FY2023 | 11.0% |
| FY2024 | 12.0% |
| FY2025 | 12.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹2,174 Cr |
| Costs | |
| Interest | ₹32 Cr |
| Expenses | ₹1,908 Cr |
| Operating profitOperating Profit | ₹265 Cr |
| Other income and charges | |
| Profit before tax | ₹199 Cr |
| Tax | |
| Net profitNet Profit | ₹157 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹2,273 Cr |
| Equity capitalEquity Capital | ₹91 Cr |
| Reserves | ₹1,160 Cr |
| Borrowings | ₹516 Cr |
| Other liabilitiesOther Liabilities | ₹506 Cr |
| AssetsTotal Assets | ₹2,273 Cr |
| Fixed assetsFixed Assets | ₹761 Cr |
| Capital work in progressCWIP | ₹273 Cr |
| Investments | ₹42 Cr |
| Other assetsOther Assets | ₹1,196 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹220 Cr |
| Investing cash flowCash from Investing Activity | -₹135 Cr |
| Financing cash flowCash from Financing Activity | -₹85 Cr |
| Change in cashNet Cash Flow | ₹1 Cr |
Learn while you research
Academy chapters picked for Aarti Drugs Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Business Cycles & StocksThese cyclical sectors win and lose in different macro phases.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read